Symbols / LIMN $0.19 +6.23% Liminatus Pharma, Inc.
LIMN Chart
About
Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 7.31M |
| Enterprise Value | 8.96M | Income | -10.21M | Sales | — |
| Book/sh | -0.06 | Cash/sh | 0.01 | Dividend Yield | — |
| Payout | 0.00% | Employees | — | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | -3.05 | P/C | — |
| EV/EBITDA | -3.02 | EV/Sales | — | Quick Ratio | 0.03 |
| Current Ratio | 0.05 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.43 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | — | ROA | -62.65% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 39.33M |
| Shs Float | 29.07M | Short Float | — | Short Ratio | 0.22 |
| Short Interest | — | 52W High | 33.66 | 52W Low | 0.16 |
| Beta | — | Avg Volume | 9.05M | Volume | 1.01M |
| Target Price | — | Recom | None | Prev Close | $0.17 |
| Price | $0.19 | Change | 6.23% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.19
Latest analyst target
3. DCF / Fair value
$3.27
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.19
Low
—
High
—
Mean
—
- New 'don't-eat-me' cancer antibody to be tested in Liminatus lung trial - Stock Titan ue, 17 Mar 2026 07
- symbol__ Stock Quote Price and Forecast - CNN Mon, 05 May 2025 22
- Liminatus Pharma, Inc. (LIMN) Stock Price, News, Quote & History - Yahoo! Finance Canada hu, 01 May 2025 00
- LIMN down 26.83% intraday: Liminatus Pharma (NASDAQ) 09 Feb 2026 earnings ahead - meyka.com Mon, 09 Feb 2026 08
- LIMN Stock Price, Quote & Chart | LIMINATUS PHARMA INC-CL A (NASDAQ:LIMN) - ChartMill Sun, 20 Jul 2025 13
- Liminatus Pharma (LIMN) jumps in premarket after late-session spike as Nasdaq $1 rule hangs over shares - TechStock² ue, 03 Feb 2026 08
- Liminatus Pharma (NASDAQ: LIMN) faces cash strain, dilution and Nasdaq listing risks - Stock Titan ue, 31 Mar 2026 21
- Liminatus Pharma prices $4 million public offering at $0.29 per share - Investing.com ue, 17 Feb 2026 08
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga ue, 03 Feb 2026 08
- 3 Penny Stocks to Watch Now, 2/5/26 - tipranks.com hu, 05 Feb 2026 08
- [8-K] Liminatus Pharma, Inc. Reports Material Event | LIMN 8-K Filing - Stock Titan Mon, 09 Feb 2026 08
- 12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga Fri, 06 Feb 2026 08
- Liminatus Pharma, Inc. Announces Pricing of $4.0 Million Public Offering - finance.yahoo.com ue, 17 Feb 2026 08
- Liminatus Pharma stock soars after engaging Digital Offering for capital raise - Investing.com hu, 24 Jul 2025 07
- Liminatus Pharma (NASDAQ: LIMN) signs MOU for $30M earn-out with Capital Trust Group - Stock Titan hu, 30 Oct 2025 07
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
2.97
-10.88%
|
3.33
-30.90%
|
4.82
+77.89%
|
2.71
|
| Research And Development |
|
0.00
-100.00%
|
2.69
-28.52%
|
3.76
+102.75%
|
1.85
|
| Selling General And Administration |
|
2.97
+360.40%
|
0.64
-39.30%
|
1.06
+24.07%
|
0.86
|
| General And Administrative Expense |
|
2.97
+360.40%
|
0.64
-39.30%
|
1.06
+24.07%
|
0.86
|
| Other Gand A |
|
2.97
+360.40%
|
0.64
-39.30%
|
1.06
+24.07%
|
0.86
|
| Total Expenses |
|
2.97
-10.88%
|
3.33
-30.90%
|
4.82
+77.89%
|
2.71
|
| Operating Income |
|
-2.97
+10.88%
|
-3.33
+30.90%
|
-4.82
-77.89%
|
-2.71
|
| Total Operating Income As Reported |
|
-2.97
+10.88%
|
-3.33
+30.90%
|
-4.82
-77.89%
|
-2.71
|
| EBITDA |
|
-9.99
-211.43%
|
-3.21
+33.30%
|
-4.81
-77.52%
|
-2.71
|
| Normalized EBITDA |
|
-10.45
-225.66%
|
-3.21
+33.30%
|
-4.81
-77.52%
|
-2.71
|
| Reconciled Depreciation |
|
0.00
|
0.00
|
—
|
—
|
| EBIT |
|
-9.99
-211.48%
|
-3.21
+33.30%
|
-4.81
-77.52%
|
-2.71
|
| Total Unusual Items |
|
0.46
|
0.00
|
—
|
—
|
| Total Unusual Items Excluding Goodwill |
|
0.46
|
0.00
|
—
|
—
|
| Special Income Charges |
|
0.40
|
0.00
|
—
|
—
|
| Other Special Charges |
|
-0.40
|
—
|
—
|
—
|
| Net Income |
|
-10.21
-187.81%
|
-3.55
+28.85%
|
-4.98
-70.22%
|
-2.93
|
| Pretax Income |
|
-10.21
-187.81%
|
-3.55
+28.85%
|
-4.98
-70.22%
|
-2.93
|
| Net Non Operating Interest Income Expense |
|
-0.14
+35.61%
|
-0.22
-31.12%
|
-0.17
+24.66%
|
-0.22
|
| Interest Expense Non Operating |
|
0.22
-36.29%
|
0.34
+93.65%
|
0.17
-20.09%
|
0.22
|
| Net Interest Income |
|
-0.14
+35.61%
|
-0.22
-31.12%
|
-0.17
+24.66%
|
-0.22
|
| Interest Expense |
|
0.22
-36.29%
|
0.34
+93.65%
|
0.17
-20.09%
|
0.22
|
| Interest Income Non Operating |
|
0.08
-37.49%
|
0.12
+1125.26%
|
0.01
|
0.00
|
| Interest Income |
|
0.08
-37.49%
|
0.12
+1125.26%
|
0.01
|
0.00
|
| Other Income Expense |
|
-7.10
|
—
|
—
|
—
|
| Other Non Operating Income Expenses |
|
-7.56
|
—
|
—
|
—
|
| Gain On Sale Of Security |
|
0.05
|
—
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-10.21
-187.81%
|
-3.55
+28.85%
|
-4.98
-70.22%
|
-2.93
|
| Net Income From Continuing Operation Net Minority Interest |
|
-10.21
-187.81%
|
-3.55
+28.85%
|
-4.98
-70.22%
|
-2.93
|
| Net Income From Continuing And Discontinued Operation |
|
-10.21
-187.81%
|
-3.55
+28.85%
|
-4.98
-70.22%
|
-2.93
|
| Net Income Continuous Operations |
|
-10.21
-187.81%
|
-3.55
+28.85%
|
-4.98
-70.22%
|
-2.93
|
| Normalized Income |
|
-10.66
-200.68%
|
-3.55
+28.85%
|
-4.98
-70.22%
|
-2.93
|
| Net Income Common Stockholders |
|
-10.21
-187.81%
|
-3.55
+28.85%
|
-4.98
-70.22%
|
-2.93
|
| Diluted EPS |
|
—
|
-0.14
+28.85%
|
-0.19
-70.22%
|
-0.11
|
| Basic EPS |
|
—
|
-0.14
+28.85%
|
-0.19
-70.22%
|
-0.11
|
| Basic Average Shares |
|
—
|
26.01
+0.00%
|
26.01
+0.00%
|
26.01
|
| Diluted Average Shares |
|
—
|
26.01
+0.00%
|
26.01
+0.00%
|
26.01
|
| Diluted NI Availto Com Stockholders |
|
-10.21
-187.81%
|
-3.55
+28.85%
|
-4.98
-70.22%
|
-2.93
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
0.51
-90.52%
|
5.41
+141.25%
|
2.24
-67.24%
|
6.84
|
| Current Assets |
|
0.50
-90.52%
|
5.28
+135.68%
|
2.24
-67.25%
|
6.84
|
| Cash Cash Equivalents And Short Term Investments |
|
0.34
+499.54%
|
0.06
-87.02%
|
0.43
-91.40%
|
5.05
|
| Cash And Cash Equivalents |
|
0.34
+499.54%
|
0.06
-87.02%
|
0.43
-91.40%
|
5.05
|
| Cash Financial |
|
0.34
+499.54%
|
0.06
-87.02%
|
0.43
-91.40%
|
5.05
|
| Receivables |
|
0.00
-100.00%
|
3.67
+288.20%
|
0.94
+845.00%
|
0.10
|
| Loans Receivable |
|
0.00
-100.00%
|
3.67
+347.92%
|
0.82
|
0.00
|
| Prepaid Assets |
|
—
|
—
|
0.00
-100.00%
|
1.68
|
| Current Deferred Assets |
|
0.00
-100.00%
|
1.40
+66.82%
|
0.84
|
0.00
|
| Other Current Assets |
|
0.16
+4.77%
|
0.16
+606.82%
|
0.02
+120.00%
|
0.01
|
| Total Non Current Assets |
|
0.01
-90.39%
|
0.13
+12621.60%
|
0.00
+0.00%
|
0.00
|
| Net PPE |
|
0.01
+1198.72%
|
0.00
-5.90%
|
0.00
+0.00%
|
0.00
|
| Non Current Accounts Receivable |
|
—
|
0.13
|
—
|
—
|
| Total Liabilities Net Minority Interest |
|
10.33
-58.27%
|
24.75
+37.22%
|
18.04
+2.17%
|
17.65
|
| Current Liabilities |
|
10.30
-58.39%
|
24.75
+37.22%
|
18.04
+2.17%
|
17.65
|
| Payables And Accrued Expenses |
|
8.36
+74.96%
|
4.78
+140.48%
|
1.99
+72.25%
|
1.15
|
| Payables |
|
8.15
+135.55%
|
3.46
+152.61%
|
1.37
+92.42%
|
0.71
|
| Accounts Payable |
|
0.58
-60.75%
|
1.48
+58.98%
|
0.93
+83.66%
|
0.51
|
| Other Payable |
|
7.36
|
—
|
0.24
|
—
|
| Current Accrued Expenses |
|
0.20
-84.49%
|
1.32
+113.49%
|
0.62
+39.68%
|
0.44
|
| Current Debt And Capital Lease Obligation |
|
1.44
-92.78%
|
19.97
+24.44%
|
16.05
-2.73%
|
16.50
|
| Current Debt |
|
1.44
-92.78%
|
19.97
+24.44%
|
16.05
-2.73%
|
16.50
|
| Other Current Borrowings |
|
1.44
-92.78%
|
19.97
+24.44%
|
16.05
-2.73%
|
16.50
|
| Current Deferred Liabilities |
|
0.50
|
0.00
|
—
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.03
|
0.00
|
0.00
|
0.00
|
| Stockholders Equity |
|
-9.81
+49.25%
|
-19.34
|
0.00
|
0.00
|
| Common Stock Equity |
|
-9.81
+49.25%
|
-19.34
-22.45%
|
-15.79
-46.11%
|
-10.81
|
| Capital Stock |
|
0.00
+54.63%
|
0.00
|
—
|
—
|
| Common Stock |
|
0.00
+54.63%
|
0.00
|
—
|
—
|
| Preferred Stock |
|
0.00
|
0.00
|
—
|
—
|
| Share Issued |
|
27.06
+4.04%
|
26.01
+0.00%
|
26.01
+0.00%
|
26.01
|
| Ordinary Shares Number |
|
27.06
+4.04%
|
26.01
+0.00%
|
26.01
+0.00%
|
26.01
|
| Additional Paid In Capital |
|
29.05
+211.63%
|
9.32
|
—
|
—
|
| Retained Earnings |
|
-38.87
-35.61%
|
-28.67
-14.12%
|
-25.12
-24.75%
|
-20.14
|
| Total Equity Gross Minority Interest |
|
-9.81
+49.25%
|
-19.34
-22.45%
|
-15.79
-46.11%
|
-10.81
|
| Total Capitalization |
|
-9.81
+49.25%
|
-19.34
-22.45%
|
-15.79
-46.11%
|
-10.81
|
| Working Capital |
|
-9.80
+49.67%
|
-19.47
-23.25%
|
-15.79
-46.10%
|
-10.81
|
| Invested Capital |
|
-8.37
-1422.75%
|
0.63
+147.24%
|
0.26
-95.50%
|
5.69
|
| Total Debt |
|
1.44
-92.78%
|
19.97
+24.44%
|
16.05
-2.73%
|
16.50
|
| Net Debt |
|
1.10
-94.45%
|
19.92
+27.54%
|
15.62
+36.36%
|
11.45
|
| Net Tangible Assets |
|
-9.81
+49.25%
|
-19.34
|
0.00
|
0.00
|
| Tangible Book Value |
|
-9.81
+49.25%
|
-19.34
-22.45%
|
-15.79
-46.11%
|
-10.81
|
| Derivative Product Liabilities |
|
0.03
|
0.00
|
—
|
—
|
| Duefrom Related Parties Current |
|
—
|
—
|
0.13
+26.00%
|
0.10
|
| Duefrom Related Parties Non Current |
|
0.00
-100.00%
|
0.13
|
—
|
—
|
| Dueto Related Parties Current |
|
0.21
-89.40%
|
1.98
+352.53%
|
0.44
+114.22%
|
0.20
|
| General Partnership Capital |
|
—
|
—
|
4.61
-10.60%
|
5.16
|
| Interest Payable |
|
0.20
-78.65%
|
0.96
+55.05%
|
0.62
+39.68%
|
0.44
|
| Limited Partnership Capital |
|
—
|
—
|
4.71
+13.13%
|
4.17
|
| Total Partnership Capital |
|
—
|
—
|
-15.79
-46.11%
|
-10.81
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-9.96
-586.62%
|
-1.45
+56.62%
|
-3.35
-284.93%
|
-0.87
|
| Cash Flow From Continuing Operating Activities |
|
-9.96
-586.62%
|
-1.45
+56.62%
|
-3.35
-284.93%
|
-0.87
|
| Net Income From Continuing Operations |
|
-10.21
-187.81%
|
-3.55
+28.85%
|
-4.98
-70.22%
|
-2.93
|
| Depreciation Amortization Depletion |
|
0.00
|
0.00
|
—
|
—
|
| Depreciation |
|
0.00
|
0.00
|
—
|
—
|
| Depreciation And Amortization |
|
0.00
|
0.00
|
—
|
—
|
| Other Non Cash Items |
|
-0.08
|
—
|
—
|
0.90
|
| Operating Gains Losses |
|
7.31
|
—
|
—
|
—
|
| Gain Loss On Investment Securities |
|
-0.05
|
—
|
—
|
—
|
| Gain Loss On Sale Of PPE |
|
7.36
|
0.00
|
—
|
—
|
| Change In Working Capital |
|
-6.98
-433.34%
|
2.10
+27.84%
|
1.64
+41.42%
|
1.16
|
| Change In Receivables |
|
-3.43
|
0.00
|
—
|
—
|
| Change In Prepaid Assets |
|
—
|
—
|
1.68
+76.71%
|
0.95
|
| Change In Payables And Accrued Expense |
|
-3.88
-274.19%
|
2.23
+176.15%
|
0.81
+273.61%
|
0.22
|
| Change In Accrued Expense |
|
0.22
-69.11%
|
0.70
+299.36%
|
0.17
+60.55%
|
0.11
|
| Change In Payable |
|
-4.10
-367.90%
|
1.53
+142.03%
|
0.63
+490.65%
|
0.11
|
| Change In Account Payable |
|
-4.04
-37448.53%
|
-0.01
-102.53%
|
0.42
+377.53%
|
0.09
|
| Change In Other Working Capital |
|
—
|
—
|
-0.84
|
—
|
| Change In Other Current Assets |
|
0.32
+343.61%
|
-0.13
-1010.43%
|
-0.01
-20.00%
|
-0.01
|
| Investing Cash Flow |
|
-0.79
+72.35%
|
-2.85
-247.99%
|
-0.82
|
0.00
|
| Cash Flow From Continuing Investing Activities |
|
-0.79
+72.35%
|
-2.85
-247.99%
|
-0.82
|
0.00
|
| Net PPE Purchase And Sale |
|
-0.01
|
0.00
|
—
|
—
|
| Purchase Of PPE |
|
-0.01
|
0.00
|
—
|
—
|
| Capital Expenditure |
|
-0.01
|
—
|
—
|
—
|
| Net Other Investing Changes |
|
-0.78
+72.81%
|
-2.85
-247.99%
|
-0.82
|
—
|
| Financing Cash Flow |
|
11.03
+181.23%
|
3.92
+971.78%
|
-0.45
-107.61%
|
5.92
|
| Cash Flow From Continuing Financing Activities |
|
11.03
+181.23%
|
3.92
+971.78%
|
-0.45
-107.61%
|
5.92
|
| Net Issuance Payments Of Debt |
|
3.04
-22.51%
|
3.92
+971.78%
|
-0.45
-118.62%
|
2.42
|
| Issuance Of Debt |
|
4.34
+10.63%
|
3.92
+15.18%
|
3.41
-63.93%
|
9.44
|
| Repayment Of Debt |
|
-1.30
|
0.00
+100.00%
|
-3.86
+45.11%
|
-7.03
|
| Short Term Debt Issuance |
|
4.34
+10.63%
|
3.92
+15.18%
|
3.41
-63.93%
|
9.44
|
| Short Term Debt Payments |
|
-1.30
|
0.00
+100.00%
|
-3.86
+45.11%
|
-7.03
|
| Net Short Term Debt Issuance |
|
3.04
-22.51%
|
3.92
+971.78%
|
-0.45
-118.62%
|
2.42
|
| Net Common Stock Issuance |
|
10.56
|
0.00
|
0.00
-100.00%
|
3.50
|
| Common Stock Payments |
|
—
|
—
|
0.00
+100.00%
|
-0.70
|
| Repurchase Of Capital Stock |
|
—
|
—
|
0.00
+100.00%
|
-0.70
|
| Net Other Financing Charges |
|
-2.56
|
—
|
—
|
—
|
| Changes In Cash |
|
0.28
+174.41%
|
-0.38
+91.81%
|
-4.61
-191.40%
|
5.05
|
| Beginning Cash Position |
|
0.06
-87.03%
|
0.43
-91.39%
|
5.05
|
0.00
|
| End Cash Position |
|
0.34
+499.54%
|
0.06
-87.02%
|
0.43
-91.40%
|
5.05
|
| Free Cash Flow |
|
-9.98
-587.52%
|
-1.45
+56.62%
|
-3.35
-284.93%
|
-0.87
|
| Interest Paid Supplemental Data |
|
—
|
—
|
0.00
-100.00%
|
0.50
|
| Income Tax Paid Supplemental Data |
|
—
|
—
|
0.00
|
0.00
|
| Change In Interest Payable |
|
0.22
-36.29%
|
0.34
+93.65%
|
0.17
+60.55%
|
0.11
|
| Common Stock Issuance |
|
10.56
|
0.00
|
0.00
-100.00%
|
4.20
|
| Issuance Of Capital Stock |
|
10.56
|
0.00
|
0.00
-100.00%
|
4.20
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-K2026-03-31 View
- 8-K2026-03-04 View
- 8-K2026-02-18 View
- 8-K2026-02-09 View
- 8-K2026-01-26 View
- 8-K2025-11-25 View
- 10-Q2025-11-14 View
- 10-Q2025-10-06 View
- 8-K2025-08-25 View
- 8-K2025-08-14 View
- 8-K2025-07-17 View
- 8-K2025-07-11 View
- 8-K2025-07-03 View
- 8-K2025-06-24 View
- 8-K2025-06-24 View
- 8-K2025-06-04 View
- 10-Q2025-06-02 View
- 8-K2025-05-06 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|